研究员,计算机辅助药物设计/Research Investigator, CADD(博士)当面告知

百濟神州有限公司
2026-12-15 15:28:34
校招博士27届

岗位详情

地区:

北京
·
上海

专业要求:

药物化学

岗位职责:

Job Overview: We are seeking a highly self-motivated Ph.D. with solid scientific background, outstanding computational capabilities, strong logical thinking, and smooth communication etc. to help accelerate drug discovery projects. Main responsibility: 1. Support drug discovery projects at various stages from CADD perspective including but not limited to structure prediction, virtual screening, hit triage, rational design etc. 2. Apply state-of-art computational methods including physics-based and data-driven approaches to the most appropriate application scenario for each project. 3. Assist assay development by probe design etc. 4. Perform SAR analysis and provide optimization direction/suggestions to the project team. 5. Provide druggability assessment for drug target evaluation and participate in proposing new targets. 6. Work closely with medicinal chemists, biologists, data/AIDD scientists, and other functions. Basic Qualifications 1. PhD in CADD, computational chemistry/biology, medicinal chemistry or closely related area with strong track record of scientific publications including patents. 2. Expertise in using CADD/AIDD technologies such as molecular docking, MD simulation, free energy perturbation, structure prediction AI models, quantum mechanics, cheminformatics, etc. 3. Familiar with common software such as Schrodinger, MOE, etc 4. Good understanding of underlying methodologies as well as their pros and cons. 5. Strong verbal and written communication skills and ability to work independently and cooperatively. 6. Comfortable to work in a fast-paced and highly collaborative environment. Preferred Qualifications 1. Experience with drug discovery projects and rational drug design. 2. Good understanding of biology or having related training. 3. Experience with scripting language or machine/deep learning techniques.

招聘要求:

Job Overview: We are seeking a highly self-motivated Ph.D. with solid scientific background, outstanding computational capabilities, strong logical thinking, and smooth communication etc. to help accelerate drug discovery projects. Main responsibility: 1. Support drug discovery projects at various stages from CADD perspective including but not limited to structure prediction, virtual screening, hit triage, rational design etc. 2. Apply state-of-art computational methods including physics-based and data-driven approaches to the most appropriate application scenario for each project. 3. Assist assay development by probe design etc. 4. Perform SAR analysis and provide optimization direction/suggestions to the project team. 5. Provide druggability assessment for drug target evaluation and participate in proposing new targets. 6. Work closely with medicinal chemists, biologists, data/AIDD scientists, and other functions. Basic Qualifications 1. PhD in CADD, computational chemistry/biology, medicinal chemistry or closely related area with strong track record of scientific publications including patents. 2. Expertise in using CADD/AIDD technologies such as molecular docking, MD simulation, free energy perturbation, structure prediction AI models, quantum mechanics, cheminformatics, etc. 3. Familiar with common software such as Schrodinger, MOE, etc 4. Good understanding of underlying methodologies as well as their pros and cons. 5. Strong verbal and written communication skills and ability to work independently and cooperatively. 6. Comfortable to work in a fast-paced and highly collaborative environment. Preferred Qualifications 1. Experience with drug discovery projects and rational drug design. 2. Good understanding of biology or having related training. 3. Experience with scripting language or machine/deep learning techniques.

公司介绍

百濟神州有限公司

百濟神州有限公司

百濟神州有限公司,成立于2018-06-28,位于香港,登记状态:仍注册,注册资本15.4142万美元,公司类型:中外合资

百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。其产品包括六种内部开发、临床阶段的候选药物,其中包括三种后期临床候选药物,zanubrutinib(BTK抑制剂),tislelizumab(PD-1抗体)与pamiparib(PARP抑制剂)。百济神州亦获得五种药物及在研药物的授权许可,包括三种已于中国销售的由新基独家授权的药物ABRAXANE、REVLIMID 及VIDAZA,及两种临床阶段的在研药物,该种药物已获得于中国及亚太地区的其他指定国家开发及商业化的权利。百济神州于2010年于北京成立并在2016年2月在美国纳斯达克全球精选市场上市。截至2018年7月,公司拥有一支超过1300名员工的全球团队,成为一家拥有涵盖研究、临床开发、生产及商业化的全面实力的全球生物技术公司。